Table 3.

Comparison of disease characteristics at the end of the study between patients who died and those who were alive at the end of the study. Data are n (%) unless otherwise indicated.

CharacteristicsAliveDeadpOR (95% CI)
Age, yrs, ± SD (n)58.4 ± 13.0 (420)70.4 ± 13.7 (44)< 0.0011.08 (1.05–1.11)
Duration PsA, yrs, ± SD (n)20.3 ± 10.9 (419)21.4 ± 13.7 (44)0.5661.01 (0.98–1.04)
Duration PsO, yrs, ± SD (n)29.9 ± 14.9 (399)37.9 ± 19.3 (39)0.0031.03 (1.01–1.05)
BMI, ± SD (n)27.7 ± 5.2 (370)27.2 ± 4.7 (30)0.6360.98 (0.91–1.06)
DAI, mean ± SD (n)3.87 ± 0.82 (411)4.49 ± 1.13 (43)< 0.0011.94 (1.43–2.64)
Male209 (50)25 (57)0.3730.75 (0.40–1.41)
Smoking (ever)224 (54)24 (60)0.5051.25 (0.65–2.43)
Hypertension181 (43)24 (55)0.1571.56 (0.84–2.92)
Hyperlipidemia66 (16)5 (11)0.4350.68 (0.26–1.79)
Diabetes49 (12)9 (20)0.0991.93 (0.87–4.25)
Destructive/deforming disease204 (49)29 (67)0.0212.16 (1.11–4.21)
bDMARD (ever)55 (13)2 (4.5)0.0980.31 (0.74–1.34)
sDMARD (ever)285 (68)27 (61)0.3830.75 (0.40–1.43)
NSAID (ever)303 (72)24 (54)0.0140.46 (0.24–0.86)
Oral corticosteroid treatment (ever)123 (29)20 (46)0.0282.00 (1.07–3.76)
Fulfilling CASPAR criteria378 (90)40 (91)0.8821.08 (0.37–3.18)
Polyarthritis (according to Moll and Wright)*173 (41)24 (54)0.0881.71 (0.92–3.20)
Dactylitis (ever)119 (41)10 (33)0.4210.72 (0.33–1.60)
Nail involvement (ever)162 (53)16 (48)0.6400.84 (0.41–1.73)
Axial involvement65 (15)14 (32)0.0062.54 (1.28–5.05)
Axial and peripheral joint involvement35 (8.3)11 (24)< 0.0013.65 (1.70–7.86)
  • * 1973 Moll and Wright criteria for PsA. PsA: psoriatic arthritis; PsO: psoriasis; BMI: body mass index; DAI: disease activity index; DMARD: disease-modifying antirheumatic drug; bDMARD: biological DMARD; sDMARD: synthetic DMARD; NSAID: nonsteroidal antiinflammatory drug; CASPAR: ClASsification for Psoriatic ARthritis (criteria).